Search Results
Jun 04, 2026, 09:00 ET Cob, the Sorghum Snack Brand Co-Founded by Novak Djokovic, Is Coming for the Tortilla Chip Aisle
sorghum story is the real one. An ancient superfood with a naturally light pop and soft hull, sorghum is a resistant starch, which can naturally boost GLP-1s to keep you fuller longer. It is packed with antioxidant polyphenols and gut-friendly prebiotic fiber, rich in magnesium, iron, and zinc, and has
More news about: Cob Foods
Jun 04, 2026, 08:31 ET MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor
More news about: MetaVia Inc.
Jun 04, 2026, 05:08 ET 歐洲腎臟協會大會：FLOW 試驗指出，司美格魯肽可改善糖尿病及腎病患者的生活質素
在不同患者亞組當中，所見的益處大致相同。研究的主要作者 Johannes Mann 教授說：「司美格魯肽為生活質素帶來的改善程度超乎我們所想，因為這些好處不單止在臨床上有意義，還在身體機能和整體安康等日常生活的多個方面持續體現出來。」Mann 教授續稱：「我們原本對生活質素的結果有所保留，皆因在腸胃出現的副作用在 GLP-1 受體激動劑中很常見。 我們的發現確認了司美格魯肽對慢性腎病的效益，不僅限於傳統的臨床指標，還包括對患者切身重要的主觀療效結果。」
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA学術大会（ERA Congress）：FLOW試験、糖尿病と腎疾患を併存する患者におけるセマグルチドと生活の質改善との関連を示す
効果の大きさには驚きました。臨床的に意義があるだけでなく、身体機能や全般的なウェルビーイングを含む日常生活のさまざまな側面にわたり、一貫した改善が認められたためです」と、本試験の筆頭著者であるJohannes Mann教授は述べました。さらに、Mann教授は次のように述べました。「GLP-1受容体作動薬では胃腸系の副作用がよく見られるため、QOLに関する転帰がどのようになるかは不確かでした。今回の知見は、慢性腎臓病におけるセマグルチドの有益性が、従来の臨床エンドポイントにとどまらず、患者にとって直接的な意義を持つ主観的転帰にも及ぶことを確認するものです。」
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA 총회: FLOW 임상시험, 세마글루타이드가 당뇨병 및 신장 질환 환자의 삶의 질 개선과 관련 있음을 보여줘
만(Johannes Mann) 교수는 "세마글루타이드에서 나타난 삶의 질 개선 효과의 규모에 놀랐다. 이는 임상적으로 의미 있을 뿐만 아니라 신체 기능과 전반적인 웰빙을 포함한 일상생활의 여러 측면에서 일관되게 경험됐기 때문이다"라고 말했다.만 교수는 이어 "GLP-1 수용체 작용제에서는 위장관 부작용이 흔하기 때문에 삶의 질 결과에 대해 확신할 수 없었다"며 "이번 연구 결과는 만성 신장 질환에서 세마글루타이드의 이점이 전통적인 임상 평가변수를 넘어 환자에게 직접적으로 중요한 주관적 결과까지 확장된다는 점을 확인해 준다"고 덧붙였다.
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
Professor Johannes Mann, study lead author."We were uncertain about quality-of-life outcomes because gastrointestinal side effects are common with GLP-1 receptor agonists," Prof. Mann furthered. "Our findings confirm that the benefits of semaglutide in chronic kidney disease extend beyond traditional
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows
Johannes Mann, study lead author."We were uncertain about quality-of-life outcomes because gastrointestinal side effects are common with GLP-1 receptor agonists," Prof. Mann furthered. "Our findings confirm that the benefits of semaglutide in chronic kidney disease extend beyond traditional
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA-Kongress: Die FLOW-Studie zeigt, dass Semaglutid die Lebensqualität bei Diabetes und Nierenerkrankungen verbessert
Hauptautor der Studie."Wir waren uns nicht sicher, wie es um die Lebensqualität bestellt ist, denn gastrointestinale Nebenwirkungen sind bei GLP-1-Rezeptor-Agonisten häufig", so Prof. Mann weiter. "Unsere Ergebnisse bestätigen, dass der Nutzen von Semaglutid bei chronischer Nierenerkrankung über
More news about: ERA Congress
Jun 03, 2026, 18:01 ET ERA Congress: Semaglutida ligada a melhor qualidade de vida em diabetes e doença renal, mostra teste DE FLUXO
estudo."Estávamos incertos sobre os resultados da qualidade de vida porque os efeitos colaterais gastrointestinais são comuns com os agonistas do receptor de GLP-1", acrescentou o Prof. Mann. "Nossas descobertas confirmam que os benefícios da semaglutida na doença renal crônica se estendem além dos desfechos clínicos
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congrès de l'ERA : L'essai FLOW montre que le sémaglutide est associé à une meilleure qualité de vie dans le diabète et les maladies rénales
certains des résultats en termes de qualité de vie, car les effets secondaires gastro-intestinaux sont fréquents avec les agonistes des récepteurs du GLP-1, » a ajouté le professeur Mann. « Nos résultats confirment que les bénéfices du semaglutide dans l'insuffisance rénale chronique vont au-delà des critères
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: Semaglutida vinculada a una mejor calidad de vida en la diabetes y la enfermedad renal, muestra EL ENSAYO FLOW
estábamos seguros de los resultados de la calidad de vida porque los efectos secundarios gastrointestinales son comunes con los agonistas del receptor GLP-1", continuó el profesor Mann. "Nuestros hallazgos confirman que los beneficios de la semaglutida en la enfermedad renal crónica se extienden más allá
More news about: ERA Congress
Jun 03, 2026, 18:01 ET Congreso ERA: El ensayo FLOW muestra beneficios de la semaglutida
dudas sobre los resultados en la calidad de vida debido a que los efectos secundarios gastrointestinales son comunes con los agonistas del receptor GLP-1", añadió el profesor Mann. "Nuestros hallazgos confirman que los beneficios de la semaglutida en la enfermedad renal crónica van más allá de los criterios
More news about: ERA Congress
Jun 03, 2026, 12:04 ET RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak
that opaganib is not effective against the indications for which we develop our products; the risk that RHB-102 (Bekinda) does not effectively reduce GLP-1/GIP-related nausea, vomiting and diarrhea; the risk regarding the Company's ability to regain and maintain compliance with Nasdaq's listing requirements,
More news about: RedHill Biopharma Ltd.
Jun 03, 2026, 11:30 ET SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
North American pharmaceutical and biotech manufacturers with bringing their specialized biologics and therapeutics to market. Its 27,000 square foot GLP-compliant facility delivers bioanalysis across both pre-clinical and clinical phases of the drug development life cycle, accommodating quick turnaround
More news about: SGS
Jun 02, 2026, 13:30 ET Kroger Health, along with Hy-Vee, Convenes Industry Leaders to Shape the Future of Health at Nourishing Change Conference
As chronic disease, GLP-1 adoption, and food for health reshape American healthcare, Kroger Health gathers leaders to explore the grocery store's emerging role as America's most scaled health infrastructureDES
More news about: The Kroger Co.
Jun 02, 2026, 11:15 ET Injectable Drug Delivery Market Size to Grow from US$655.1 Billion in 2026 to US$1182.2 Billion by 2033 | Persistence Market Research
demand for insulin pens, prefilled syringes, and injectable GLP-1 therapies.Cancer treatment is generating parallel demand growth. Modern oncology increasingly relies on injectable biologics, immunotherapies,
More news about: Persistence Market Research Pvt. Ltd.
Jun 02, 2026, 09:00 ET The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts
parties and are subject to significant uncertainty; and the size and persistence of demand in the GLP-1-driven skin laxity category depends on continued adoption of GLP-1 therapies, patient outcomes, and reimbursement dynamics, all of which are subject to change.In
More news about: Equity Insider
Jun 02, 2026, 08:32 ET True Salt Positions Premium Sea Salt as the Reformulation Ingredient of Choice for Food Manufacturers
salt as a long-term reformulation solution."Additional market trends are further accelerating reformulation efforts. Increased use of GLP-1 medications, heightened scrutiny of artificial ingredients, and growing consumer demand for transparency are all driving interest in simpler ingredient
More news about: True Salt
Jun 02, 2026, 08:00 ET The Scale Built for the GLP-1 Era
DEXA1 (Fat Mass: up to 99% correlation, Muscle Mass: up to 98%).¹NEW GLP-1 Muscle Protection to Ensure You're Losing Fat, Not Muscle: For GLP-1 users, protecting essential muscle mass during rapid weight loss is crucial. Withings BodyFit provides
More news about: Withings
Jun 02, 2026, 08:00 ET RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results
More news about: RedHill Biopharma Ltd.
Jun 02, 2026, 02:54 ET 晶泰科技研發食品級口服肽Tensotide™獲美國Self-GRAS認證，AI設計分子破局千億代謝健康消費品市場
全球肥胖與高血糖人群持續激增，代謝健康已成為最剛性的消費需求之一。根據弗若斯特沙利文報告，全球減重保健食品市場 2025 年已突破 200 億美元，中國市場年複合增長率超過 14%。當前，市場上的控糖減重產品普遍面臨 「有效的不安全、安全的效果弱、效果好的價格高」 的困局。GLP-1 類處方藥雖療效明確，但價格昂貴、需注射給藥，而口服制劑使用限制條件多，且整體存在胃腸與甲狀腺相關副作用警示，僅限醫囑範圍內使用，難以覆蓋大眾日常健康管理場景。在口服產品領域，各技術路線同樣存在明顯短板：傳統保健品如苦瓜素、白芸豆提取物等天然植物成分，作用機理模糊、臨床證據不足，效果難以標準化
More news about: 晶泰科技
Jun 01, 2026, 21:32 ET Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital
platform is expected to help businesses launch direct-to-consumer healthcare brand in a matter of days in all 50 states. Compliant offerings include: GLP-1s, peptides, personalized healthcare treatments, sermorelin, testosterone replacement therapy ("TRT"), hair loss, skincare, sexual health and more. Hydreight
More news about: Hydreight Technologies Inc.
Jun 01, 2026, 16:05 ET Cirius Therapeutics Announces Presentation on CIR-0602K as Novel Diabetes Treatment at the American Diabetes Association's 2026 Scientific Sessions
beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the synergistic transformation of subcutaneous adipose tissue includes dramatic
More news about: Cirius Therapeutics
Jun 01, 2026, 12:30 ET Parker Waichman LLP Files Lawsuit on behalf of Pennsylvania Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy
Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
Jun 01, 2026, 11:34 ET Camurus announces expansion of Lilly collaboration
compound class. The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual GLP-1 and GIP and receptor agonists, triple agonists for GLP-1, GIP and glucagon receptor agonists, and amylin receptor agonists."Lilly's decision to exercise the option validates
More news about: Camurus AB